Tevogen Bio Holdings Inc. · NASDAQ:TVGN
Tevogen Bio — SPAC Merger (November 2023)
37 slides from Tevogen Bio's SPAC merger presentation, Nov 16, 2023
Slide 1: Corporate Overview
Oncology Neurology Virology A healthier world is possible when lifesaving innovations are within the reach of all CORPORATE OVERVIEW
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including without limitation statements relating to the business combination (the “Transaction”) between Tevogen Bio Inc (“Tevogen”) and Semper Paratus Acquisition Corporation (“Semper Paratus”), including the
Slide 3: About Semper Paratus Acquisition Corporation
About Semper Paratus Acquisition Corporation Semper Paratus Acquisition Corporation Management Team Focus Suren Ajjarapu Semper Paratus Acquisition Corporation (Nasdaq: LGST) is a special • CEO of Semper Paratus purpose acquisition company formed for the purpose of effecting a • 25+ years of experie
Slide 4: Transaction Overview
Transaction Overview Key Transaction Highlights Illustrative Sources & Uses • Semper Paratus Acquisition Corporation (LGST) has agreed • Advance TVGN 489 through completion of a potentially pivotal to purchase Tevogen Bio Inc. (“Tevogen”) at an enterprise clinical trial in acute COVID-19 patients wi
Slide 5: It's the insight behind the investment, not its magnitude
It's the insight behind the investment, not its magnitude, that will pave the way for a healthier tomorrow Health Care System Performance Compared to Spending x) : oe se tee t08 US Health Spending Edges uc 6 Forbes Past $4.3 Trillion as Covid ioe we sue Brags On et a $6.16 Billion Per Drug December
Slide 6: Affordability and Accessibility mission
Affordability To be the very first biotechnology company offering commercially attractive, economically viable, and cost-effective personalized T cell therapies for large populations. Accessibility To leverage our advanced science and innovative business models to overcome both socioeconomic and geo
Slide 7: Pioneering industry leaders and scientists
In our first chapter, Tevogen Bio has developed quickly from concept to innovative clinical-stage biotech company, with a successful proof-of-concept trial of the first clinical product from its next generation T cell therapy platform, robust intellectual property portfolio, R&D facilities and labor
Slide 8: Clinical-stage specialty immunotherapy company
We are a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (“CD8+ CTLs” or “CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disor
Slide 9: Tevogen moved its first product from discovery to clinic within 18 months
May 2021 Dec ‘21 - Jan ‘22 Feb - May 2022 Jan 2023 Nov 2023 Ambulatory acute-risk 3 granted US patents Established corporate Ambulatory acute-risk/ Potential clinical COVID-19 treatment (now: also 7 pending, headquarters in New immunocompromised manufacturing IND cleared by FDA 5 ex-US patent Jersey
Slide 10: Public listing via business combination with Semper Paratus
Tevogen Bio to become publicly listed via business combination with Semper Paratus Acquisition Corporation, at an expected enterprise value of $1.2 billion — June 28, 2023 NEW YORK STOCK faxCHANGE S BioSNJ ImNOWTION eueaERTNSS
Slide 11: Leadership team
"When affordability of lifesaving medications is paired with a profitable business model, society prospers" - Tevogen Leadership, June 2020 Ryan Saadi, MD, Neal Flomenberg, Sadiq Khan, MBA Kirti Desai, CPA Stephen Chen, Mittul Mehta Dolores Grosso, Judy Akhtar, MPH MD Chief Commercial Chief Financia
Slide 12: Board of Directors & Corporate Advisory Board
Board of Directors & Corporate Advisory Board Ryan Saadi, MD, MPH Curtis Patton, PhD Susan Podlogar, MBA Lindee Goh, PhD Jeffrey Feike, MPH Chair, Board of Directors Board of Directors Board of Directors Board of Directors Board of Directors CEO, Tevogen Bio; Professor Emeritus of Chief HR Officer,
Slide 13: Tevogen's T Cell Therapy Platform - ExacTcell
Tevogen's T Cell Therapy Platform - ExacTcell TM Designed to overcome key hurdles to unlock the full potential of T Cell Therapies Virology Oncology Neurology ExacTcell focuses on the selection and expansion of naturally occurring, genetically unmodified CD8+ CTLs to target multiple, distinct, prese
Slide 14: Uniqueness of ExacTcell Platform
Uniqueness of ExacTcell Platform TM Autologous CAR-T Platform Allogeneic* CAR-T Platform Tevogen's ExacTcell Platform Target antigens present on both healthy Target antigens present on both healthy and diseased cells Target antigens present only on diseased cells and diseased cells Genetically modif
Slide 15: CD8+ CTLs Identify and Kill Infected or Malignant Cells
CD8+ CTLs Identify and Kill Infected or Malignant Cells Through the Recognition of Antigenic Peptides on Their Surfaces Most CTLs, including those developed with ExacTcell, express T cell receptors (“TCRs”), which are surface proteins that provide each T cell with its unique immune specificity to re
Slide 16: Potentially the First Personalized Immunotherapy for Large Patient Populations
Potentially the First Personalized Immunotherapy for Large Patient Populations T lymphocytes CD8+ cell education Target specific Cytotoxic CD8+ Rapid HLA matched from donor to recognize multiple cytotoxic CD8+ lymphocytes expanded to therapeutic infused in proactively selected lymphocyte yield hundr
Slide 17: Product Development Prioritization: Prevalence, Unmet Need & Access Landscape
Product Development Prioritization: Prevalence, Unmet Need & Access Landscape COVID-19 Long COVID Oncology Annual US incidence: 1.9M Cancer Statistics, 2021 - PubMed (nih.gov) Marketed products: 2,629 Pharma commercial intelligence, news & analysis | Evaluate Download date: Dec 01, 2022 Clinical pip
Slide 18: Product Development Prioritization: Prevalence, Unmet Need & Access Landscape
Product Development Prioritization: Prevalence, Unmet Need & Access Landscape There had been an estimated In addition, 103 million an estimated 15.1% of all cumulative confirmed U.S. adults COVID-19 cases have experienced in the United States alone as of Long COVID as of May 17, 2023.1 May 8, 20232
Slide 19: TVGN 489: The First Clinical Product of ExacTcell
TVGN 489: The First Clinical Product of ExacTcell Designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. Antigen-presenting cell Antigen HLA Class-1 CD8 TCR Inf
Slide 20: TVGN 489 Was Designed to Overcome Expected Mutational Challenges
TVGN 489 Was Designed to Overcome Expected Mutational Challenges Most monoclonal antibodies lasted only months prior to market withdrawal and vaccines are requiring yearly revisions, but almost three years into development, TVGN 489’s COVID-19 peptide targets remain well preserved despite the contin
Slide 21: TVGN 489 Was Designed to Overcome the Mutational Challenges of COVID-19
TVGN 489 Was Designed to Overcome the Mutational Challenges of COVID-19 Each dose level concluded with three patients rather than six and the treatment arm concluded with a total of 12 patients rather than 24, primarily due to the absence of appreciable toxicities across all dose levels. The compara
Slide 22: Proof of Concept Clinical Trial – Interventional Arm Patient Profiles
TVGN 489 Proof of Concept Clinical Trial – Interventional Arm Patient Profiles Patient Age Comorbidities Vaccination Status Variant Dosing Level 1 (1 x 105 cells/kg) African Amer Male 24 Obesity, HTN, DM, Asthma Unvaccinated Delta Caucasian Female 73 Obesity, HTN, Age Vaccinated Delta Hispanic Femal
Slide 23: Positive Proof-of-Concept Clinical Trial – Key Observations
Positive Proof-of-Concept Clinical Trial – Key Observations Dose-Limiting Toxicity Criteria Trial Result Interventional Versus Observational ≥ Grade 3 acute infusion reaction None Day Started to Feel Better Cytokine release syndrome None (Hypoxia and/or Hypotension) Neurotoxicity None Graft versus H
Slide 24: Rapid Viral Load Reduction After TVGN 489 Treatment
Positive Proof-of-Concept Clinical Trial - Rapid Viral Load Reduction After TVGN 489 Treatment Percent Virus Eliminated COVID-19 viral presence was assessed by PCR in Thomas Patients Day 4 Day 7 Day 10 Day 14 Jefferson University’s Clinical Pathology Laboratory. 1 100.00% 100.00% 100.00% 100.00% Bas
Slide 25: Positive Proof-of-Concept Clinical Trial – Key Observations
Positive Proof-of-Concept Clinical Trial – Key Observations TVGN 489 COVID-19 reactive CD8+ T cells in treatment arm patients detected throughout the six month follow up. “Product-only clone” refers to any T cell expressing a T cell receptor with a DNA sequence found in the investigational product (
Slide 26: Long COVID: Eradication and Restoration
Long COVID: Eradication and Restoration Recent studies1 show that some Long COVID patients have lingering viral proteins, suggesting a persistent viral reservoir. This finding indicates that TVGN 489 CTLs could potentially be used to eliminate this reservoir and restore homeostasis. SARS-CoV-2 Reser
Slide 27: ExacTcell in Oncology
ExacTcell in Oncology Lacking PD-1, our product should still function, even if oncology target cells express PD-L1. PD-L1 binds to PD-1 and inhibits T cell Blocking PD-L1 or PD-1 allows T cell Blocking PD-L1 or PD-1 may not allow Lacking PD1 & alike, we believe TVGN killing of tumor cell killing of
Slide 28: ExacTcell in Oncology
ExacTcell in Oncology Unlike CAR-T or Bispecific T-cell Engager (BiTE) antibody approaches, which recruit a heterogeneous group of T cells to the tumor, our approach would instead focus a highly purified population of CTLs on the tumor, which we believe may provide more potential to accomplish the t
Slide 29: Robust Research Pipeline
Robust Research Pipeline We are committed to developing lifesaving therapies for viral diseases and cancers with high unmet need. Therapy Candidate Target Indication Target Population Discovery / Phase 1 / Safety Data Phase 2 Phase 3 Preclinical Available1 (Potentially Pivotal2) B-cell cancer immune
Slide 30: Addressing the Needs of Large Patient Populations
Addressing the Needs of Large Patient Populations TVGN 601 – Multiple Sclerosis Nearly one million people in the United States are living with MS1 2.8 million people are estimated to live with MS worldwide6 TVGN 930 – EBV-Associated Lymphomas EBV-related cancers have an incidence rate of 6.68 per 10
Slide 31: Pathway to Revenue
Pathway to Revenue Reflects management’s current assumptions, estimates, projections and beliefs March 2021 April 2021 May 2021 Oct 2021 June 2020 Tevogen Founded TVGN 489 TVGN 489 TVGN 489 ambulatory TVGN 489 first pre-clinical first clinical acute-risk COVID-19 patient treated completed batch manu
Slide 32: Tevogen.ai introduction
TEVOGEN . Cn \ “ | Welcome to the forefront of NG i innovation in the biotech industry, N= _/where human expertise and artificial UUTLUTLUT LITLE intelligence merge to redefine the limits of scientific exploration e = Affordability and access for all are at the heart of Tevogen’s vision. In pursuit
Slide 33: Tevogen.ai Aims to Enhance Patient Access Using AI
Tevogen.ai Aims to Enhance Patient Access by Utilizing Artificial Intelligence-powered Tools Novel drug discovery | Enhance precision and success rates | Decrease costs and development time Target Detection: We are exploring ways to deploy AI-powered Loss of exclusivity Loss of exclusivity target de
Slide 34: Healthcare Reimagined: Vision 2025
Healthcare Reimagined: Vision 2025 Where Efficiency Meets Equality with Integrated Solutions Healthcare is one $4.3 trillion of the largest U.S. health care spending grew 2.7 percent in 2021, sectors of the reaching $4.3 trillion or US economy Tevogen Holdings $12,914 per person. Vision 2025 Histori
Slide 35: Advancing the clinical development of TVGN 489
Advancing the clinical development of TVGN 489 for the treatment of COVID-19 and Long COVID • Launch a pivotal trial in COVID-19 patients with B cell malignancies in early 2024. • Launch clinical trials in Long COVID in approximately the second quarter of 2024. Leveraging our ExacTcell platform to d
Slide 36: One Vision, One Community, a Healthier Tomorrow
One Vision, One Community, a Healthier Tomorrow Diversity & Inclusion Summi : under and CEO that s the foundation ‘of American success. ‘fwe lose that key concept we will not only forfet our status. {asthe global leader in “innovation, we wil reject our identity as “Americans. Keynote Speaker M.D.,
Slide 37: Please Contact us with Investor Inquiries
Please Contact us with Investor Inquiries at: ir@tevogen.com 1 877-TEVOGEN